Clinical Scorecard: A Shift in Strategy for Ocular Melanoma
At a Glance
| Category | Detail |
|---|---|
| Condition | Small Choroidal Melanoma |
| Key Mechanisms | Early treatment improves survival and preserves vision; genetic testing for diagnostic evaluation. |
| Target Population | Patients with small choroidal melanomas, average age 58. |
| Care Setting | Ocular oncology and retina clinics. |
Key Highlights
- Early intervention significantly reduces mortality rates.
- Gene expression profiling (GEP) aids in risk stratification.
- 5-year incidence of metastasis varies by tumor class: 2% (class 1A), 20% (class 1B), 70% (class 2).
- Average tumor thickness decreased from 1.8 mm to 1.3 mm post-treatment.
- Vision improved to 20/30 in treated patients.
Guideline-Based Recommendations
Diagnosis
- Utilize vitreoretinal surgical approach for diagnosis.
- Incorporate gene expression profiling for risk assessment.
Management
- Early surgical intervention with vitrectomy and laser ablation.
- Suppress inflammation with steroids.
Monitoring & Follow-up
- Regular follow-up to assess tumor size and vision changes.
Risks
- Class 2 tumors have a high mortality risk (50%-70% at 5 years).
Patient & Prescribing Data
226 patients with small choroidal melanomas.
99% received diagnostic testing; significant functional recovery observed.
Clinical Best Practices
- Shift from delayed observational treatment to early intervention.
- Focus on anatomical and visual benefits of treatment.
References
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.